Key terms
About THRD
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest THRD news
Apr 01
10:10pm ET
Third Harmonic Bio (NASDAQ:THRD) Soars 109% YTD; Is It a Solid Bet for Growth Investors?
Mar 28
5:02pm ET
Third Harmonic Bio Welcomes New Director, Geoff McDonough
Mar 28
8:44am ET
Third Harmonic Bio appoints McDonough to board of directors
Mar 26
2:15pm ET
Buy Rating for Third Harmonic Bio Amidst Promising Drug Pipeline and Market Potential
Mar 26
10:16am ET
TD Cowen Remains a Buy on Third Harmonic Bio, Inc. (THRD)
Jan 04
8:22am ET
Third Harmonic says IND-enabling toxicology studies of THB335 nearing completion
Jan 04
8:21am ET
Third Harmonic appoints Christopher Murphy as chief financial, business officer
No recent press releases are available for THRD
THRD Financials
Key terms
Ad Feedback
THRD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
THRD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
